← Back to all signals
REGN · Q2 2026

REGENERON PHARMACEUTICALS, INC.

Reported 2026-07-30
BEAT
51EarnIQ signal
↗

Confidence rising

Mild quarter-over-quarter shift

Strong commercial execution, pipeline progress, and Sanofi debt payoff drive double-digit growth and increased guidance.

  • ✓Guidance was raised, with high specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Headline confirmed

Management confidence reinforces the reported beat.

EPS: reported vs expected+36.5%$14.29 vs $10.47
Revenue: reported vs expected+10.2%$4.3B vs $3.9B
Guidance specificityHighRaised
Market expectations supplied by Finnhub · Reported vs consensus estimate

Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline

✦
EarnIQ Premium

Understand exactly why confidence changed.

Unlock management-language evidence, guidance specificity, the pressure point, narrative breaks, risks, and quarter-over-quarter topic changes.

Guidance specificityPressure pointNarrative breakSource evidence
Preview full report